Meeting
2019 ASCO Annual Meeting
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.
Authors
Vincent Chung
City of Hope, Duarte, CA
Vincent Chung , Ling Wang , Margaret S. Fletcher , Erminia Massarelli , Karen L. Reckamp , Mihaela C. Cristea , Nikeeta Prajapati , Aruna Parikh , Roger Lewis Whiting , Maggie Wang , Jay Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT03556228
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS3146)
DOI
10.1200/JCO.2019.37.15_suppl.TPS3146
Abstract #
TPS3146
Poster Bd #
138a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
First Author: Noah Federman
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2022 ASCO Annual Meeting
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.
First Author: Xiao-Li Wei
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong